Utility Values for Advanced Soft Tissue Sarcoma Health States from the General Public in the United Kingdom

Table 3

Mean utilities (95% confidence intervals) for ASTS health states, stratified by respondents’ cancer status and elicitation method.

	Mean utilities (95% confidence intervals) for
	Progressive disease	Stable disease	Partial response	Complete response
Utilities elicited using TTO
Whole cohort	0.30 (0.26; 0.34)	0.43 (0.39; 0.47)	0.51 (0.47; 0.55)	0.60 (0.57; 0.64)
Respondents with cancer	0.16 (0.06; 0.27)*	0.26 (0.17; 0.35)**	0.34 (0.25; 0.44)***	0.48 (0.36; 0.60)****
Respondents without cancer	0.31 (0.26; 0.35)*	0.44 (0.40; 0.49)**	0.53 (0.48; 0.57)***	0.61 (0.58; 0.65)****
Utilities elicited using SG
Whole cohort	0.17 (0.14; 0.19)	0.31 (0.29; 0.34)	0.43 (0.40; 0.45)	0.51 (0.49; 0.53)
Respondents with cancer	0.07 (0.01; 0.12)^†	0.21 (0.15; 0.28)^††	0.32 (0.25; 0.39)^†††	0.42 (0.34; 0.50)^††††
Respondents without cancer	0.18 (0.14; 0.21)^†	0.32 (0.30; 0.35)^††	0.44 (0.41; 0.46)^†††	0.52 (0.49; 0.54)^††††

* 𝑃<0.05; **𝑃<0.02; ***𝑃=0.01; ****𝑃=0.05; ^†𝑃<0.03; ^††𝑃<0.02; ^†††𝑃<0.01; ^††††𝑃<0.05.